Vanda Pharmaceuticals/$VNDA
1D1W1MYTD1Y5YMAX
Capital at risk
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
- Ticker
- $VNDA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 533
- Headquarters
- Washington, United States
- Website
- www.vandapharma.com
VNDA Metrics
BasicAdvanced
$309M
-
-$4.63
0.64
-
Price and volume
Market cap
$309M
Beta
0.64
52-week high
$9.94
52-week low
$4.27
Average daily volume
884K
Financial strength
Current ratio
1.612
Quick ratio
1.401
Long term debt to equity
0.083
Total debt to equity
0.083
Profitability
EBITDA (TTM)
-177.041
Gross margin (TTM)
93.74%
Net profit margin (TTM)
-127.41%
Operating margin (TTM)
-86.07%
Effective tax rate (TTM)
-55.11%
Revenue per employee (TTM)
$400,000
Management effectiveness
Return on assets (TTM)
-22.38%
Return on equity (TTM)
-77.81%
Valuation
Price to revenue (TTM)
1.409
Price to book
1.4
Price to tangible book (TTM)
2.89
Price to free cash flow (TTM)
-1.986
Free cash flow yield (TTM)
-50.35%
Free cash flow per share (TTM)
-2.573
Growth
Revenue change (TTM)
6.02%
Earnings per share change (TTM)
304.80%
3-year revenue growth (CAGR)
-3.27%
10-year revenue growth (CAGR)
5.24%
3-year earnings per share growth (CAGR)
162.05%
10-year earnings per share growth (CAGR)
17.02%
What the Analysts think about VNDA
Analyst ratings (Buy, Hold, Sell) for Vanda Pharmaceuticals stock.
Analyst projections of the future price of Vanda Pharmaceuticals stock.
Bulls say / Bears say
Fanapt® net product sales increased 23% year-over-year to $36.0 million in Q2 2026, with total prescriptions up 31%, demonstrating strong commercial momentum and prescriber adoption. (PR Newswire)
BYSANTI™ (milsaperidone) received FDA approval for bipolar I disorder and schizophrenia in Q1 2026, with a commercial launch expected in H2 2026, broadening Vanda’s revenue base beyond its legacy franchises. (PR Newswire)
Management reiterated full-year 2026 total revenue guidance of $240 million–$290 million, underscoring confidence in ongoing product launches and pipeline progress. (PR Newswire)
HETLIOZ® net product sales plunged 66% year-over-year to $5.6 million in Q2 2026, reflecting significant generic competition and waning demand for the legacy sleep-disorder therapy. (PR Newswire)
Loss before income taxes widened to $62.4 million in Q2 2026, compared with $34.9 million in Q2 2025, highlighting heavy investment in new product launches that continue to pressure profitability. (PR Newswire)
Fanapt® represented roughly 71% of Q2 2026 total net product sales ($36.0 million of $50.5 million), exposing Vanda to significant revenue concentration risk should demand slow. (PR Newswire)
Data summarised monthly by Lightyear AI. Last updated on 27 Aug 2026.
VNDA Financial Performance
Revenues and expenses
VNDA Earnings Performance
Company profitability
Upcoming events
No upcoming events
VNDA News
AllArticlesVideos
Funds containing VNDA
AllUSDEURGBP
Fund name | Fund size | $VNDA weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.03% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.03% |
iShares Healthcare Innovation£DRDR | £1B | 0.03% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.02% |
iShares Ageing Population€AGED | €822M | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.